Supernus Pharma (SUPN) Misses Q2 EPS

Supernus Pharma (NASDAQ: SUPN) reported Q2 GAAP EPS of ($0.02), which may not compare to the analyst estimate of $0.22. Revenue for the quarter came in at $135.56 million versus the consensus estimate of $144.53 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Sharon AI surges premarket; New Oriental gains, Medline slips
• MIND Technology (MIND) Misses Q1 EPS by 5c